Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Syncor Xigris Delivery For Lilly Is First Non-Radiopharmacy Agreement

  • News

Executive Summary

Syncor's agreement to provide emergency delivery of Lilly's pending sepsis agent Xigris (drotrecogin alfa) is the company's first distribution deal outside of radiopharmacy.

You may also be interested in...



Cardinal To Run Xigris Emergency Distribution Via Acquisition Of Syncor

Cardinal will be the emergency supplier of Lilly's sepsis agent Xigris following the wholesaler's acquisition of the nuclear pharmacy company Syncor

Cardinal To Run Xigris Emergency Distribution Via Acquisition Of Syncor

Cardinal will be the emergency supplier of Lilly's sepsis agent Xigris following the wholesaler's acquisition of the nuclear pharmacy company Syncor

Idec Zevalin NHL Indication Split By Accelerated/Standard Approval

Idec/Genentech will conduct a postmarketing study of Zevalin in non-Hodgkin's lymphoma patients who have not failed Rituxan therapy to fulfill accelerated approval requirements

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS038422

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By